Healthcare

The rationale for early neuroprotection is to explore treatment approaches that may be relevant before all details of neurological injury are established. Development of an investigational medicine does not mean that ambulance administration is approved or clinically demonstrated. The work described by Argenica Therapeutics …

The company’s programmes use iNKT cells as a basis for engineered cell therapies. Their biological properties are being investigated for potential applications in blood cancers and solid tumours, rather than constituting proof of treatment effectiveness. The work described by Arovella Therapeutics Limited (ASX:ALA) should …

Its GaRP programme concerns a multi-component, multi-coated formulation intended to address aspects of gastrointestinal barrier function and microbiome balance. The company describes GaRP as a complementary medicine research project rather than an established cure for irritable bowel syndrome. The work described by Anatara Lifesciences …

Extracellular matrix materials can provide a structure for tissue interaction during the healing process. Aroa’s product and clinical work focuses on how these materials can be applied in surgical and wound-care settings rather than guaranteeing tissue regeneration in individual patients. The work described by …

AdAlta’s April 2026 ASX announcement described AdCella’s strategy of in-licensing T-cell therapy candidates and undertaking development work to support manufacturing and early clinical studies in regulated markets. The work described by AdAlta Limited (ASX:1AD) should be assessed against the specific product or research programme …

Transdermal and topical formulation involves selecting ingredients and delivery methods that influence how medicines interact with the skin. Product development also includes stability, manufacturing and regulatory requirements. The work described by Acrux Limited (ASX:ACR) should be assessed against the specific product or research programme …

Its research targets the 11β-HSD1 enzyme, which is involved in local cortisol production. The approach seeks to evaluate whether modifying this pathway has clinical relevance in Alzheimer’s disease. The work described by Actinogen Medical Limited (ASX:ACW) should be assessed against the specific product or …